Insider Selling: Sera Prognostics, Inc. (NASDAQ:SERA) General Counsel Sells $50,478.56 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) General Counsel Benjamin Jackson sold 7,912 shares of Sera Prognostics stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $6.38, for a total value of $50,478.56. Following the sale, the general counsel now owns 120,561 shares of the company’s stock, valued at approximately $769,179.18. This represents a 6.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Benjamin Jackson also recently made the following trade(s):

• On Friday, January 10th, Benjamin Jackson sold 13,272 shares of Sera Prognostics stock. The shares were sold at an average price of $7.42, for a total transaction of $98,478.24.
• On Monday, November 11th, Benjamin Jackson sold 4,727 shares of Sera Prognostics stock. The stock was sold at an average price of $7.32, for a total transaction of $34,601.64.

Sera Prognostics Stock Down 0.2 %

SERA stock opened at $6.60 on Friday. The company has a 50 day moving average price of $7.40 and a two-hundred day moving average price of $7.31. Sera Prognostics, Inc. has a one year low of $4.98 and a one year high of $12.35.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.09 million. During the same period in the prior year, the company posted ($0.23) earnings per share. On average, sell-side analysts anticipate that Sera Prognostics, Inc. will post -0.96 earnings per share for the current fiscal year.

Institutional Trading of Sera Prognostics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SERA. Quest Partners LLC lifted its holdings in shares of Sera Prognostics by 533.5% during the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock worth $50,000 after acquiring an additional 5,415 shares during the period. The Manufacturers Life Insurance Company acquired a new position in Sera Prognostics during the second quarter worth approximately $68,000. SG Americas Securities LLC acquired a new position in Sera Prognostics during the third quarter worth approximately $78,000. Prime Capital Investment Advisors LLC purchased a new position in Sera Prognostics during the third quarter worth approximately $104,000. Finally, Jane Street Group LLC boosted its holdings in shares of Sera Prognostics by 24.8% in the 3rd quarter. Jane Street Group LLC now owns 14,225 shares of the company’s stock valued at $111,000 after purchasing an additional 2,826 shares during the last quarter. Hedge funds and other institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.